Targeting metabolic stress to kill pancreatic cancer cells
Targeting metabolic stress to induce pancreatic tumor cell death
This study is looking at a way to help treat pancreatic cancer by blocking a protein called GOT1, which helps cancer cells survive stress, with the hope of making those cells die in a new way that could be more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10895990 on NIH RePORTER |
What this research studies
This research investigates how to induce cell death in pancreatic cancer by targeting specific metabolic pathways. The focus is on a protein called GOT1, which helps pancreatic cancer cells manage stress from reactive oxygen species. By inhibiting GOT1, the researchers aim to trigger a type of cell death known as ferroptosis, which is distinct from traditional apoptosis. The study employs advanced techniques to analyze metabolic changes and test various inhibitors to selectively kill pancreatic cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic cancer who may benefit from novel therapeutic approaches.
Not a fit: Patients with non-cancerous conditions or those with advanced-stage pancreatic cancer where treatment options are limited may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve survival rates for pancreatic cancer patients.
How similar studies have performed: Previous research has shown promise in targeting metabolic pathways in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Lyssiotis, Costas Andreas — University of Michigan at Ann Arbor
- Study coordinator: Lyssiotis, Costas Andreas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.